Published in Gene Therapy Weekly, October 26th, 2006
Study 1: Metabolic biotinylation provides a unique platform for the purification and targeting of multiple adeno-associated virus (AAV) vector serotypes.
According to recent research published in the journal Molecular Therapy, "The development of rationally designed targeted gene delivery vectors is an important focus for gene therapy. While genetic modification of AAV can produce vectors with modified tropism, incorporation of targeting peptides into the structural context of the AAV virion often results in loss of function or loss of virion integrity. To address...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2006-10-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.